Does activity of anticancer drugs in advanced cancer always translates in effectivity in early-stage high-risk disease?
Most anticancer drugs are developed in cancer patients with advanced disease, for whom no standard treatment is available.
When active, they are tested in earlier settings and finally in patients with early-stage high-risk disease to obtain an improvement in overall survival.
Many older cytotoxic anticancer drugs, which were first used in cancer patients with advanced disease, have now a place in the adjuvant treatment of patients with early-stage high-risk disease. This is the case for patients with breast cancer with the use of alkylating agents, anthracyclines and taxanes, for patients with nonsmall-cell lung cancer (NSCLC) with platinum-based regimens, colorectal cancer with fluoro-pyrimidinesbased schedules and more recently prostate cancer with taxanes [1] (Table 1) .
Also hormonal manipulation, active in advanced metastatic disease proved to be effective in earlier settings as shown in hormone-sensitive breast [e.g. tamoxifen, aromatase inhibitors and prostate cancer (biochemical castration in combination with radiotherapy)].
